Vericel Corp (NASDAQ:VCEL) Director Alan L. Rubino acquired 890 shares of the business’s stock in a transaction that occurred on Friday, March 16th. The shares were bought at an average price of $11.57 per share, with a total value of $10,297.30. Following the completion of the transaction, the director now directly owns 165 shares in the company, valued at $1,909.05. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Vericel Corp (NASDAQ VCEL) traded up $0.25 during mid-day trading on Tuesday, reaching $11.50. 415,557 shares of the company’s stock traded hands, compared to its average volume of 1,062,523. The stock has a market cap of $418.80, a PE ratio of -21.60 and a beta of 3.15. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.86 and a quick ratio of 3.57. Vericel Corp has a 12-month low of $2.35 and a 12-month high of $12.80.
Vericel (NASDAQ:VCEL) last released its earnings results on Monday, March 5th. The biotechnology company reported $0.03 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.13. The firm had revenue of $23.35 million during the quarter. Vericel had a negative net margin of 27.04% and a negative return on equity of 98.77%. equities analysts anticipate that Vericel Corp will post -0.14 earnings per share for the current year.
Hedge funds have recently added to or reduced their stakes in the business. Kopp Investment Advisors LLC grew its stake in shares of Vericel by 246.0% during the 4th quarter. Kopp Investment Advisors LLC now owns 293,070 shares of the biotechnology company’s stock valued at $1,597,000 after buying an additional 208,368 shares during the period. Goldman Sachs Group Inc. purchased a new stake in shares of Vericel during the 4th quarter valued at $105,000. Consonance Capital Management LP grew its stake in shares of Vericel by 11.8% during the 4th quarter. Consonance Capital Management LP now owns 3,381,303 shares of the biotechnology company’s stock valued at $18,428,000 after buying an additional 356,969 shares during the period. RTW Investments LP purchased a new stake in shares of Vericel during the 4th quarter valued at $7,111,000. Finally, Broadfin Capital LLC purchased a new stake in shares of Vericel during the 4th quarter valued at $472,000. 37.22% of the stock is owned by hedge funds and other institutional investors.
VCEL has been the subject of several research reports. Piper Jaffray Companies lifted their price objective on Vericel to $14.00 and gave the stock an “overweight” rating in a research report on Monday, March 5th. BTIG Research restated a “buy” rating and set a $13.00 price objective (up from $8.00) on shares of Vericel in a research report on Monday, March 5th. ValuEngine downgraded Vericel from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Ladenburg Thalmann Financial Services downgraded Vericel from a “buy” rating to a “neutral” rating in a research report on Tuesday, March 6th. Finally, Needham & Company LLC lifted their target price on shares of Vericel from $5.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, March 6th. Two analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $14.00.
COPYRIGHT VIOLATION NOTICE: “Alan L. Rubino Purchases 890 Shares of Vericel Corp (VCEL) Stock” was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://ledgergazette.com/2018/03/20/alan-l-rubino-purchases-890-shares-of-vericel-corp-vcel-stock.html.
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.